NCT06431776View on ClinicalTrials.gov

Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

August 31, 2024

Primary Completion Date

January 31, 2027

Study Completion Date

August 31, 2027

Conditions
Autoimmune Pulmonary Alveolar Proteinosis
Interventions
DRUG

Molgramostim

Molgramostim nebulizer solution will be administered once daily using a proprietary nebulizer optimized for the delivery of high molecular weight biologic compounds.

Trial Locations (1)

45229-3039

Cincinnati Children's Hospital Medical Center, Cincinnati

All Listed Sponsors
lead

Savara Inc.

INDUSTRY

NCT06431776 - Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP). | Biotech Hunter | Biotech Hunter